Horizon Pharma PLC (NASDAQ:HZNP)‘s stock had its “buy” rating reiterated by equities research analysts at Jefferies Group LLC in a research note issued to investors on Thursday. They presently have a $16.00 price objective on the biopharmaceutical company’s stock. Jefferies Group LLC’s target price would indicate a potential upside of 17.04% from the stock’s current price.

HZNP has been the subject of several other research reports. Piper Jaffray Companies set a $18.00 price target on Horizon Pharma PLC and gave the stock a “buy” rating in a report on Sunday, September 10th. BidaskClub downgraded Horizon Pharma PLC from a “buy” rating to a “hold” rating in a report on Monday, July 31st. ValuEngine downgraded Horizon Pharma PLC from a “buy” rating to a “hold” rating in a report on Friday, September 1st. Cantor Fitzgerald reissued a “buy” rating and issued a $17.00 price target on shares of Horizon Pharma PLC in a report on Tuesday, September 26th. Finally, Cowen and Company reissued a “buy” rating on shares of Horizon Pharma PLC in a report on Thursday, September 28th. Five research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $18.00.

Shares of Horizon Pharma PLC (HZNP) traded up 0.66% during trading on Thursday, reaching $13.76. The company’s stock had a trading volume of 1,036,335 shares. Horizon Pharma PLC has a 12-month low of $9.45 and a 12-month high of $21.98. The stock’s market capitalization is $2.25 billion. The firm’s 50-day moving average is $12.93 and its 200-day moving average is $12.75.

Horizon Pharma PLC (NASDAQ:HZNP) last issued its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported $0.41 earnings per share for the quarter, topping the consensus estimate of $0.12 by $0.29. The business had revenue of $289.51 million during the quarter, compared to the consensus estimate of $237.01 million. Horizon Pharma PLC had a positive return on equity of 22.85% and a negative net margin of 42.40%. The company’s quarterly revenue was up 12.5% on a year-over-year basis. During the same quarter last year, the company earned $0.56 earnings per share. Equities analysts expect that Horizon Pharma PLC will post $1.07 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Jefferies Group LLC Reaffirms Buy Rating for Horizon Pharma PLC (HZNP)” was first published by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another website, it was illegally copied and reposted in violation of US & international copyright and trademark law. The original version of this article can be accessed at https://www.americanbankingnews.com/2017/10/05/jefferies-group-llc-reaffirms-buy-rating-for-horizon-pharma-plc-hznp.html.

A number of hedge funds have recently made changes to their positions in HZNP. BlackRock Inc. raised its position in Horizon Pharma PLC by 68,479.5% during the first quarter. BlackRock Inc. now owns 13,261,212 shares of the biopharmaceutical company’s stock valued at $196,001,000 after acquiring an additional 13,241,875 shares in the last quarter. Paulson & CO. Inc. purchased a new position in Horizon Pharma PLC during the second quarter valued at approximately $58,584,000. Dimensional Fund Advisors LP raised its position in Horizon Pharma PLC by 119.4% during the second quarter. Dimensional Fund Advisors LP now owns 6,265,608 shares of the biopharmaceutical company’s stock valued at $74,373,000 after acquiring an additional 3,409,411 shares in the last quarter. William Blair Investment Management LLC purchased a new position in Horizon Pharma PLC during the second quarter valued at approximately $23,557,000. Finally, Balyasny Asset Management LLC purchased a new position in Horizon Pharma PLC during the second quarter valued at approximately $13,958,000. Institutional investors own 82.33% of the company’s stock.

About Horizon Pharma PLC

Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.

Analyst Recommendations for Horizon Pharma PLC (NASDAQ:HZNP)

Receive News & Ratings for Horizon Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.